Edition:
United Kingdom

ArQule Inc (ARQL.OQ)

ARQL.OQ on NASDAQ Stock Exchange Global Market

7.97USD
13 Sep 2019
Change (% chg)

-- (--)
Prev Close
$7.97
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
733,574
52-wk High
$12.21
52-wk Low
$2.23

Latest Key Developments (Source: Significant Developments)

Bleichroeder LP Reports 13.25% Passive Stake In ArQule Inc As Of September 1
Thursday, 5 Sep 2019 

Sept 5 (Reuters) - ArQule Inc ::BLEICHROEDER LP REPORTS 13.25% PASSIVE STAKE IN ARQULE INC AS OF SEPTEMBER 1 - SEC FILING.  Full Article

Stealth BioTherapeutics Announces Appointment Of Robert Weiskopf As Chief Financial Officer
Tuesday, 3 Sep 2019 

Sept 3 (Reuters) - Stealth BioTherapeutics Corp ::STEALTH BIOTHERAPEUTICS ANNOUNCES APPOINTMENT OF ROBERT WEISKOPF AS CHIEF FINANCIAL OFFICER.STEALTH BIOTHERAPEUTICS CORP - WEISKOPF MOST RECENTLY SERVED AS CHIEF FINANCIAL OFFICER AND TREASURER FROM 2015 TO 2019..  Full Article

ArQule Sees FY 2019 Revenue $3.0 Million To $5.0 Million
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - ArQule Inc ::ARQULE REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.08.SEES FY 2019 REVENUE $3.0 MILLION TO $5.0 MILLION.Q2 REVENUE $300,000 VERSUS $13.7 MILLION.Q2 REVENUE ESTIMATE $1 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $-0.09 -- REFINITIV IBES DATA.SEES FY 2019 LOSS PER SHARE $0.35 TO $0.37.NOW EXPECTS TO END 2019 WITH ABOUT $160 MILLION IN CASH AND MARKETABLE SECURITIES WHICH WILL SUPPORT CURRENT BUSINESS PLAN INTO 2022.  Full Article

ArQule Announces Pricing Of $90 Million Public Offering Of Common Stock
Tuesday, 25 Jun 2019 

June 25 (Reuters) - ArQule Inc ::ARQULE ANNOUNCES PRICING OF $90 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 9.25 MILLION COMMON SHARES PRICED AT $9.75PER SHARE.  Full Article

ArQule Reports Q4 Loss Per Share $0.09
Monday, 5 Mar 2018 

March 5 (Reuters) - ArQule Inc ::ARQULE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.09.SEES FY 2018 REVENUE $3.0 MILLION TO $4.0 MILLION.SEES FY 2018 LOSS PER SHARE $0.30 TO $0.34.REVENUES FOR QUARTER ENDED DECEMBER 31, 2017, WERE ZERO, COMPARED WITH REVENUES OF $1.2 MILLION FOR THE QUARTER ENDED DECEMBER 31, 2016.  Full Article

Roivant Sciences And Arqule Enter Into License Agreement For Derazantinib In China
Wednesday, 7 Feb 2018 

Feb 7 (Reuters) - Arqule Inc ::ROIVANT SCIENCES AND ARQULE ENTER INTO LICENSE AGREEMENT FOR DERAZANTINIB IN CHINA.ARQULE INC - ‍DEAL TERMS INCLUDE AN UPFRONT PAYMENT TO ARQULE OF $3 MILLION AND AN ADDITIONAL $2.5 MILLION DEVELOPMENT MILESTONE WITHIN FIRST YEAR​.ARQULE INC - ARQULE IS ALSO ELIGIBLE FOR REGULATORY AND COMMERCIAL MILESTONES AND ROYALTIES ON FUTURE SALES OF DERAZANTINIB IN GREATER CHINA.ARQULE INC - COLLABORATION BETWEEN CO AND ROIVANT WILL EXPAND CLINICAL DEVELOPMENT OF DERAZANTINIB.ARQULE - ‍ GRANTED A ROIVANT UNIT AN EXCLUSIVE LICENSE TO DEVELOP, COMMERCIALIZE DERAZANTINIB IN PEOPLE'S REPUBLIC OF CHINA, HONG KONG, MACAU, TAIWAN​.  Full Article

ArQule Files For Offering Of Up To 17.1 Million Shares
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Arqule Inc ::ARQULE INC FILES FOR OFFERING OF UP TO 17.1 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.  Full Article

Arqule reports Q3 loss per share $0.09
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Arqule Inc :Arqule reports third quarter 2017 financial results.Q3 loss per share $0.09.Sees FY 2017 loss per share $0.38 to $0.40.Q3 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.Arqule Inc - ‍Expects to end 2017 with between $47 and $49 million in cash and marketable securities​.Arqule Inc - ‍For 2017, Arqule expects net use of cash to range between $25 and $27 million​.  Full Article

ArQule announces $9.5 mln private placement of preferred stock
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - ArQule Inc :ArQule announces $9.5 million private placement of preferred stock.ArQule Inc - to use proceeds to advance clinical trials related to proprietary pipeline, including derazantinib, miransertib, ARQ 531 & ARQ 751​.  Full Article

Arqule announces $15.7 mln private placement of common stock
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Arqule Inc :Arqule announces $15.7 million private placement of common stock.Arqule Inc - ‍intends to use net proceeds from offering to advance clinical trials related to its proprietary pipeline​.Arqule Inc - expects in first part of 2019 to obtain arq 531 PK/PD data from phase 1a trial in patients with refractory b-cell malignancies.Arqule inc - ‍company currently anticipates cash and marketable securities to provide funding into 2019​.Arqule Inc - ‍expects to end 2017 with between $38 and $40 million in cash and marketable securities​.Arqule Inc - expects in first part of 2019 to initiate phase 1b proof of concept trial​ for arq 531.Arqule-Expects in first part of 2019 to present authorities with proof of concept data to initiate registrational trial in proteus syndrome​ for ARQ 092.  Full Article